355 related articles for article (PubMed ID: 3114883)
1. Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties.
Lijnen HR; Stump DC; Collen DC
Semin Thromb Hemost; 1987 Apr; 13(2):152-9. PubMed ID: 3114883
[No Abstract] [Full Text] [Related]
2. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
3. Thrombolytic therapy in the eighties.
Verstraete M; Collen D
Blood; 1986 Jun; 67(6):1529-41. PubMed ID: 2423156
[No Abstract] [Full Text] [Related]
4. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
5. [Tissue plasminogen activator: mechanism of action and thrombolytic properties].
Páramo JA; Collen D
Sangre (Barc); 1984; 29(4-C):767-73. PubMed ID: 6393389
[No Abstract] [Full Text] [Related]
6. Potentiation of the thrombolytic efficacy of single-chain urokinase (Pro-urokinase) by heparin.
Gulba DC; Fischer K; Reil GH; Daniel WG; Lichtlen PR
Thromb Haemost; 1988 Oct; 60(2):350-1. PubMed ID: 3146150
[No Abstract] [Full Text] [Related]
7. Thrombolytic treatment in acute myocardial infarction.
Acar J; Vahanian A; Michel PL; Slama M; Cormier B; Roger V
Semin Thromb Hemost; 1987 Apr; 13(2):186-200. PubMed ID: 2957791
[No Abstract] [Full Text] [Related]
8. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
Czyrski J
Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Holmes WE; Collen D
J Biol Chem; 1988 Apr; 263(12):5594-8. PubMed ID: 2965704
[TBL] [Abstract][Full Text] [Related]
10. Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase).
Gurewich V; Pannell R
Semin Thromb Hemost; 1987 Apr; 13(2):146-51. PubMed ID: 3114882
[No Abstract] [Full Text] [Related]
11. Molecular mechanism of action of newer thrombolytic agents.
Collen D
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
[TBL] [Abstract][Full Text] [Related]
12. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
14. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
15. Newer thrombolytic drugs for acute myocardial infarction.
Reddy DS
Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
[TBL] [Abstract][Full Text] [Related]
16. [Thrombolytic therapy in acute myocardial infarct].
Bode C; Baumann H; von Hodenberg E; Kübler W
Med Klin (Munich); 1992 Feb; 87(2):64-9. PubMed ID: 1542285
[No Abstract] [Full Text] [Related]
17. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
[TBL] [Abstract][Full Text] [Related]
18. [Molecular mechanisms of thrombolytic therapy].
Lijnen HR; Collen D
Haemostasis; 1986; 16 Suppl 4():3-15. PubMed ID: 2945768
[No Abstract] [Full Text] [Related]
19. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
Van de Werf F; Jang IK; Collen D
J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
[TBL] [Abstract][Full Text] [Related]
20. New approaches to thrombolytic therapy.
Collen D; Lijnen HR
Arteriosclerosis; 1984; 4(6):579-85. PubMed ID: 6439177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
